Avila Therapeutics, a biotechnology company, has appointed Andrew Hirsch as its first chief financial officer (CFO). Hirsch joins Avila from Biogen Idec where he spent the past 10 years in a number of roles of increasing responsibility – most recently as vice president of corporate strategy and merger and acquisition (M&A).
Hirsch’s prior roles during his tenure at Biogen Idec included responsibilities in the finance organisation for corporate planning, budget development and management, and investor relations.
Hirsch led business development for a software start-up company and spent several years in management consulting at Stern Stewart & Co and The Parthenon Group. He graduated from the University of Pennsylvania with a BA in Economics and holds a MBA from The Tuck School at Dartmouth College.
The annual BNP Paribas Cash Management University kicked off on Thursday morning with treasury professionals congregating in Paris from across Europe.
APIs may be a solution to MT940 challenges, says Karen Fagan, treasury operation manager, for British television company, ITV.
Kicking off the first day of the Singapore Fintech Festival, issues with cryptocurrencies were addressed by MIT media labs director, Joi Ito, and panels of technology leaders discussed how they’re using data analytics.
Sibos 2017 day two highlights: Brexit and banking, and why ‘data is the new oil’ in financial services
How nation first politics can impact global financial organisations It’s clear that data and regulation are the two key topics that are ... read more